Full Text

Turn on search term navigation

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Brown adipose tissue activation increases energy expenditure and has been shown to improve glucose tolerance, making it a promising target for the treatment of obesity and type 2 diabetes. Brown adipocytes differentiate into cells with multilocular lipid droplets, which can efficiently absorb and oxidize glucose; however, the mechanisms regulating these processes are not completely understood. We conducted a genome-wide loss-of-function screen using a CRISPR-based approach to identify genes that promote or inhibit adipogenesis and glucose uptake in brown adipocytes. We validated genes that negatively or positively regulated these pathways and verified that the E3-ubiquitin ligase Rfwd2 suppressed brown adipocyte glucose uptake. Brown adipocytes with CRISPR-targeted Rfwd2 deletion showed an altered proteomic landscape and increased basal, as well as insulin-stimulated, glucose uptake. These data reveal the complexity of genetic regulation of brown adipogenesis and glucose metabolism.

Details

Title
A CRISPR Screen Identifies the E3 Ubiquitin Ligase Rfwd2 as a Negative Regulator of Glucose Uptake in Brown Adipocytes
Author
Lynes, Matthew D 1   VIAFID ORCID Logo  ; Huang, Qian 2 ; Cora, Carolina 3 ; Sheng-Chiang, Su 4 ; Peng, Yi 5 ; Yu-Hua, Tseng 5   VIAFID ORCID Logo 

 Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, ME 04074, USA; Department of Medicine, Maine Health, Portland, ME 04101, USA; Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME 04469, USA; Roux Institute at Northeastern University, Portland, ME 04101, USA 
 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA; [email protected] (Q.H.); [email protected] (S.-C.S.); 
 Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, ME 04074, USA; Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME 04469, USA 
 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA; [email protected] (Q.H.); [email protected] (S.-C.S.); ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 
 Section on Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA; [email protected] (Q.H.); [email protected] (S.-C.S.); ; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA 
First page
1865
Publication year
2023
Publication date
2023
Publisher
MDPI AG
e-ISSN
20734425
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2882552054
Copyright
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.